EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections

Manasi Haval, Chandrashekhar Unakal iD, Shridhar C Ghagane, Bijay Raj Pandit, Esther Daniel, Parbatee Siewdass, Kingsley Ekimeri iD, Vijayanandh Rajamanickam iD, Angel Justiz-Vaillant iD, Kathy-Ann A Lootawan, Fabio Muniz De Oliveira iD, Nivedita Bashetti und 3 weitere

Antibiotics · 28.08.2025 · 14 (9) · 865

DOI: 10.3390/antibiotics14090865 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 28.08.2025. Verfasst von Manasi Haval und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pre-Clinical Research and Drug Development, Cytxon Biosolutions Pvt. Ltd., Hubballi 580031, Karnataka, India. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 309 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biofilms constitute a significant challenge in the therapy of infectious diseases, offering remarkable resistance to both pharmacological treatments and immunological elimination. This resilience is orchestrated through the regulation of extracellular polymeric molecules, metabolic dormancy, and quorum sensing, enabling biofilms to persist in both clinical and industrial environments. The resulting resistance exacerbates chronic infections and contributes to mounting economic burdens. This review examines the molecular and structural complexities that drive biofilm persistence and critically outlines the limitations of conventional diagnostic and therapeutic approaches. We emphasize advanced technologies such as super-resolution microscopy, microfluidics, and AI-driven modeling that are reshaping our understanding of biofilm dynamics and heterogeneity. Further, we highlight recent progress in biofilm-targeted therapies, including CRISPR-Cas-modified bacteriophages, quorum-sensing antagonists, enzyme-functionalized nanocarriers, and intelligent drug-delivery systems responsive to biofilm-specific cues. We also explore the utility of in vivo and ex vivo models that replicate clinical biofilm complexity and promote translational applicability. Finally, we discuss emerging interventions grounded in synthetic biology, such as engineered probiotic gene circuits and self-regulating microbial consortia, which offer innovative alternatives to conventional antimicrobials. Collectively, these interdisciplinary strategies mark a paradigm shift from reactive antibiotic therapy to precision-guided biofilm management. By integrating cutting-edge technologies with systems biology principles, this review proposes a comprehensive framework for disrupting biofilm architecture and redefining infection treatment in the post-antibiotic era.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial resistantbacteriabiofilmbiofilm quantificationnanomaterialsquorum sensing

Autor:innen und Institutionen

  • Department of Pre-Clinical Research and Drug Development, Cytxon Biosolutions Pvt. Ltd., Hubballi 580031, Karnataka, India.
  • Department of Pathology/Microbiology & Pharmacology, The University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago.
  • KAHER's Dr. Prabhakar Kore Basic Science Research Centre, KLE Academy of Higher Education and Research, JNMC Campus, Belagavi 590010, Karnataka, India.
  • School of Nursing, Faculty of Medical Sciences, The University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago.
  • Optometry Unit-Clinical Surgical Science, The University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago.
  • Department of Computing and Information Technology, The University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago.

ORCID-Profile: Chandrashekhar Unakal, Kingsley Ekimeri, Vijayanandh Rajamanickam, Angel Justiz-Vaillant, Fabio Muniz De Oliveira

Zitieren

APA

Haval, M., Unakal, C., Ghagane, S. C., Pandit, B. R., Daniel, E., Siewdass, P., Ekimeri, K., Rajamanickam, V., Justiz-Vaillant, A., Lootawan, K. A., Oliveira, F. M., Bashetti, N., Naqvi, T. A., Shettar, A., & Bhasme, P. (2025). Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections. Antibiotics, 14(9), 865. https://doi.org/10.3390/antibiotics14090865

Vancouver

Haval M, Unakal C, Ghagane SC, Pandit BR, Daniel E, Siewdass P, et al. Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections. Antibiotics. 2025;14(9):865. doi:10.3390/antibiotics14090865

BibTeX
@article{Haval2025,
  author = {Haval, Manasi and Unakal, Chandrashekhar and Ghagane, Shridhar C and Pandit, Bijay Raj and Daniel, Esther and Siewdass, Parbatee and Ekimeri, Kingsley and Rajamanickam, Vijayanandh and Justiz-Vaillant, Angel and Lootawan, Kathy-Ann A and Oliveira, Fabio Muniz De and Bashetti, Nivedita and Naqvi, Tatheer Alam and Shettar, Arun and Bhasme, Pramod},
  title = {Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections},
  journal = {Antibiotics},
  year = {2025},
  volume = {14},
  number = {9},
  pages = {865},
  doi = {10.3390/antibiotics14090865}
}
Kostenlos starten →